Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 41, Issue 11, 2014, Pages 2104-2113

  Maksymowych, Walter P ^a   Naides, Stanley J ^d   Bykerk, Vivian ^c,f   Siminovitch, Katherine A ^c   Van Schaardenburg, Dirkjan ^j   Boers, Maarten ^h   Landewé, Robert ⁱ   Van Der Heijde, Désirée ^k   Tak, Paul P ⁱ   Genovese, Mark C ^e   Weinblatt, Michael E ^g   Keystone, Edward C ^c   Zhukov, Olga S ^d   Abolhosn, Rania W ^d   Popov, Joanna M ^d   Britsemmer, Karin ^j   Van Kuijk, Arno W ⁱ   Marotta, Anthony ^b,l  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Augurex Life Sciences Corp   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f HOSPITAL FOR SPECIAL SURGERY   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF AMSTERDAM   (Netherlands)

^j Reade   (Netherlands)

^k LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

Biomarker; C reactive protein anticitrullinated; Protein antibodies rheumatoid factor; Rheumatoid arthritis; Serum 14 3 3

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; PROTEIN 14 3 3; PROTEIN 14 3 3ETA; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY SCORE; DISEASE ASSOCIATION; DISEASE MARKER; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SEROLOGY; AREA UNDER THE CURVE; BLOOD; CANADA; CASE CONTROL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE COURSE; MIDDLE AGED; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PHYSIOLOGIC MONITORING; PROCEDURES; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SEVERITY OF ILLNESS INDEX;

14-3-3 PROTEINS; ADULT; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; BIOMARKERS; CANADA; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PROGNOSIS; REFERENCE VALUES; RHEUMATOID FACTOR; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 84923263522     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131446     Document Type: Article

References (20)

1. Tanikawa C, Ueda K, Nakagawa H., Yoshida N, Nakamura Y, Matsuda K. Regulation of protein Citrullination through p53/PADI4 network in DNA damage response. Cancer Res 2009; 69:8761-9.
2. Sokka T. Work disability in early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21:S71-4.
3. Verstappen SM, Bijlsma JW, Verkleij H, Buskens E., Blaauw AA, ter Borg EJ, et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 2004; 51:488-97.
4. Young A, Dixey J, Kulinskaya E., Cox N, Davies P, Devlin J., et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 2002; 61:335-40.
5. Vermeer M, Kuper HH, Hoekstra M, Haagsma C.J., Posthumus MD, Brus HL, et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum 2011; 63:2865-72.
6. Aletaha D, Neogi T, Silman A.J., Funovits J., Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569-81.
7. Burr ML, Viatte S, Bukhari M., Plant D, Symmons DP, Thomson W, et al. Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis. Arthritis Res Ther 2012; 14:R109.
8. Mjaavatten MD, van der Heijde DM, Uhlig T, Haugen AJ, Nygaard H, Bjørneboe O, et al. Should anti-citrullinated protein antibody and rheumatoid factor status be reassessed during the first year of followup in recent-onset arthritis? A longitudinal study. J Rheumatol 2011; 38:2336-41.
9. de Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Predicting arthritis outcomes-what can be learned from the Leiden Early Arthritis Clinic? Rheumatology 2011; 50:93-100.
10. Kilani RT, Maksymowych WP, Aitken A, Boire G., St-Pierre Y, Li Y, et al. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol 2007; 34:1650-7.
11. Chavez-Munoz C, Kilani RT, Ghahary A. Profile of exosomes related proteins released by differentiated and undifferentiated human keratinocytes. J Cell Physiol 2009; 221:221-31.
12. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009; 9:581-93.
13. Maksymowych WP, van der Heijde DM, Allaart CF, Landewé R, Boire G, Tak PP, et al. 14-3-3eta is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res Ther 2014; 16:R99.
14. Arnett FC, Edworthy SM, Bloch D.A., McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
15. Maksymowych WP, Marotta A. 14-3-3η: a novel mediator upregulated by TNFα, reflects clinical response to anti-TNFα1 therapy [abstract]. Arthritis Rheum 2011; 63 Suppl 10:S162-3.
16. Vander CB, Hoffman IE, Peene I, Union A., Mielants H, Meheus L, et al. Prediction models for rheumatoid arthritis during diagnostic investigation: evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitope. Ann Rheum Dis 2007; 66:364-9.
17. Vander Cruyssen B, Cantaert T, Nogueira L., Clavel C, De Rycke L, Dendoven A, et al. Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays. Arthritis Res Ther 2006; 8:R122.
18. Raza K, Breese M, Nightingale P., Kumar K, Potter T, Carruthers D.M., et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 2005; 32:231-8.
19. Marotta A, van Kuijk AW, Maksymowych WP, Tak PP. Serum 14-3-3η: an independent biomarker associated with joint damage in psoriatic arthritis [abstract]. Ann Rheum Dis 2012; 71 Suppl 3:S576.
20. Maksymowych WP, Landewe R, Tak P.P., Ritchlin CJ, Ostergaard M, Mease PJ, et al. Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondylarthritis: the OMERACT 9 v2 criteria. J Rheumatol 2009; 36:1785-91.